Drug Profile

Tafoxiparin - Dilafor

Alternative Names: DF-01; Tafoxiparin-Dilafor; Tafoxiparin-sodium

Latest Information Update: 07 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Dilafor
Developer Dilafor; Lee's Pharmaceutical; University of Liverpool
Class Antivirals; Glycosaminoglycans; Low molecular weight heparins
Mechanism of Action Muscle protein modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase II Dystocia; Preeclampsia
No development reported COVID 2019 infections

Most Recent Events

30 Jan 2025 Dilafor completed meetings with USFDA and European Health Agencies regarding development of Tafoxiparin
30 Jan 2025 Dilafor plans a phase III trial for Priming of labour in Europe
30 Jan 2025 Dilafor plans a phase III trial for Priming of labour in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com